Literature DB >> 15331579

Minireview: RET: normal and abnormal functions.

Massimo Santoro1, Rosa Marina Melillo, Francesca Carlomagno, Giancarlo Vecchio, Alfredo Fusco.   

Abstract

The RET gene encodes a single-pass transmembrane receptor tyrosine kinase. RET is the oncogene that causes papillary thyroid carcinoma and medullary thyroid carcinoma. The latter may arise as a component of multiple endocrine neoplasia type 2 syndromes; germline mutations in RET are responsible for multiple endocrine neoplasia type 2 inheritance. In this report we review data on the mechanisms leading to RET oncogenic conversion and on RET targeting as a strategy in thyroid cancer treatment.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15331579     DOI： 10.1210/en.2004-0922

Source DB:  PubMed          Journal:  Endocrinology        ISSN： 0013-7227            Impact factor:   4.736


  32 in total

1.  The dependence receptor Ret induces apoptosis in somatotrophs through a Pit-1/p53 pathway, preventing tumor growth.

Authors:  Carmen Cañibano; Noela L Rodriguez; Carmen Saez; Sulay Tovar; Montse Garcia-Lavandeira; Maria Grazia Borrello; Anxo Vidal; Frank Costantini; Miguel Japon; Carlos Dieguez; Clara V Alvarez
Journal:  EMBO J       Date:  2007-03-22       Impact factor: 11.598

2.  Value of routine measurement of serum calcitonin concentrations in patients with nodular thyroid disease: A multicenter study.

Authors:  G Papi; S M Corsello; K Cioni; A M Pizzini; S Corrado; C Carapezzi; G Fadda; A Baldini; C Carani; A Pontecorvi; E Roti
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

3.  Characterization of aberrant melting peaks in unlabeled probe assays.

Authors:  Shale Dames; Rebecca L Margraf; David C Pattison; Carl T Wittwer; Karl V Voelkerding
Journal:  J Mol Diagn       Date:  2007-07       Impact factor: 5.568

4.  Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability.

Authors:  Anshuman Dixit; Ali Torkamani; Nicholas J Schork; Gennady Verkhivker
Journal:  Biophys J       Date:  2009-02       Impact factor: 4.033

5.  Medullary thyroid carcinoma: a 25-year perspective.

Authors:  Xavier Matias-Guiu; Ronald De Lellis
Journal:  Endocr Pathol       Date:  2014-03       Impact factor: 3.943

6.  Overexpression of genes involved in miRNA biogenesis in medullary thyroid carcinomas with RET mutation.

Authors:  Cinzia Puppin; Cosimo Durante; Marialuisa Sponziello; Antonella Verrienti; Valeria Pecce; Elisa Lavarone; Federica Baldan; Antonio Francesco Campese; Amelie Boichard; Ludovic Lacroix; Diego Russo; Sebastiano Filetti; Giuseppe Damante
Journal:  Endocrine       Date:  2014-02-26       Impact factor: 3.633

Review 7.  The "next-generation" knowledge of papillary thyroid carcinoma.

Authors:  Valerio Costa; Roberta Esposito; Pierlorenzo Pallante; Alfredo Ciccodicola; Alfredo Fusco
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

8.  The RET E616Q Variant is a Gain of Function Mutation Present in a Family with Features of Multiple Endocrine Neoplasia 2A.

Authors:  William Grey; Rosaline Hulse; Anna Yakovleva; Dilyana Genkova; Benjamin Whitelaw; Ellen Solomon; Salvador J Diaz-Cano; Louise Izatt
Journal:  Endocr Pathol       Date:  2017-03       Impact factor: 3.943

Review 9.  Molecular pathogenesis of MEN2-associated tumors.

Authors:  Christian A Koch
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

10.  Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot.

Authors:  Petra B Musholt; Thomas J Musholt; Saskia C Morgenstern; Karl Worm; Sien-Yi Sheu; Kurt W Schmid
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.